Last $0.80 USD
Change Today -0.0005 / -0.06%
Volume 630.7K
RNN On Other Exchanges
As of 8:04 PM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

rexahn pharmaceuticals inc (RNN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/4/14 - $1.52
52 Week Low
11/17/14 - $0.65
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

rexahn pharmaceuticals inc (RNN) Related Businessweek News

No Related Businessweek News Found

rexahn pharmaceuticals inc (RNN) Details

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer. The company has three clinical stage oncology candidates: Archexin, RX-3117, and SupinoxinTM (RX-5902), as well as a pipeline of preclinical compounds to treat multiple types of cancer. Rexahn has also developed proprietary drug discovery platform technologies in the areas of Nano-Polymer-Drug Conjugate Systems (NPDCS), nano-medicines, 3D-GOLD, and TIMES. The company is based in Rockville, Maryland.

16 Employees
Last Reported Date: 03/21/14

rexahn pharmaceuticals inc (RNN) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $380.8K
President and Chief Operating Officer
Total Annual Compensation: $268.8K
Founder, Chairman of the Board and Chief Scie...
Total Annual Compensation: $319.5K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $270.1K
Compensation as of Fiscal Year 2013.

rexahn pharmaceuticals inc (RNN) Key Developments

Rexahn Pharmaceuticals, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 09:15 AM

Rexahn Pharmaceuticals, Inc. Presents at 3rd Annual SACHS Cancer Bio Partnering and Investment Forum, Feb-23-2015 09:15 AM. Venue: The New York Academy of Sciences, 7 World Trade Center, 250 Greenwich St, 40th Floor (D Elevator Bank), New York, NY10007, United States.

Rexahn Pharmaceuticals, Inc. Announces the Publication of Preclinical Data for Supinoxin(TM) (RX-5902) Demonstrating Mechanism of Action

Rexahn Pharmaceuticals, Inc. announced the release of an online publication describing preclinical results for Supinoxin™ (RX-5902) in the peer reviewed medical journal, Journal of Cellular Biochemistry, in an article titled, ‘A Novel Anti-Cancer Agent, 1-(3,5-Dimethoxyphenyl)-4-[(6-fluoro-2-methoxyquinoxalin-3-yl)aminocarbonyl] piperazine (RX-5902), Interferes with ß-Catenin Function through Y593 phospho-p68 RNA Helicase.’ The article was coauthored by Dr. Zhi-Ren Liu of the Department of Biology, at Georgia State University, and Rexahn scientists. In this study, Supinoxin was shown to directly bind to phosphorylated p68 and inhibit ß-catenin dependent ATPase activity resulting in a decrease in expression of a number of cancer related downstream genes (oncogenes) such as c-Myc, cyclin-D1 and p-cJun. The expression of these oncogenes is a key step in the growth and proliferation of cancer cells. The ability of Supinoxin to disrupt the ß-catenin/phosphorylated p68/oncogene pathway represents a novel mechanism for the inhibition of growth of human cancer cells.

Rexahn Pharmaceuticals, Inc. Appoints Ely Benaim as Chief Medical Officer

Rexahn Pharmaceuticals, Inc. announced the appointment of Ely Benaim, M.D. as Chief Medical Officer. In this role, Dr. Benaim will be responsible for leading Rexahn's clinical development programs, and providing strategic and clinical guidance for the company. Dr. Benaim has more than 25 years of experience in healthcare including 15 years of clinical research experience in academia, government and pharmaceutical industry, as well as extensive experience in global regulatory affairs. Dr. Benaim was most recently Senior Vice President of Regulatory Affairs & Chief Medical Officer of Berg Pharma.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RNN:US $0.80 USD -0.0005

RNN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RNN.
View Industry Companies

Industry Analysis


Industry Average

Valuation RNN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REXAHN PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at